Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07101094 · ClinicalTrials.gov registry record
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
A clinical trial of Schizophrenia, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 300
- Enrollment target
- 17
- Study locations
NCT07101094: Recruiting study of Schizophrenia, sponsored by Bristol-Myers Squibb.
NCT07101094 is a study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 300 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07101094, a study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Conditions Studied
Interventions
- DRUG xanomeline and trospium chloride (X/T) therapy
Study Locations (17)
Maryland
- Local Institution - 0007 - Baltimore
- Local Institution - 0017 - Bel Air
- Local Institution - 0004 - Catonsville
Massachusetts
- Local Institution - 0008 - Belmont
- Local Institution - 0002 - Boston
- Mayflower Clinical - South Dartmouth
California
- Local Institution - 0009 - Orange
- Lumos Clinical Research Center - San Jose
Texas
- Local Institution - 0012 - El Paso
- Local Institution - 0013 - Longview
Illinois
- Local Institution - 0003 - Evanston
Nebraska
- Omaha Insomnia and Psychiatric Services - Omaha
New Jersey
- Hackensack Meridian Health - Carrier Clinic - Belle Mead
New York
- Local Institution - 0015 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2029-05-14 |
What NCT07101094 shows while recruiting
NCT07101094 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which xanomeline and trospium chloride (X/T) therapy is the first listed.
NCT07101094 lists 17 locations in 11 states (Maryland, Massachusetts, California).
Frequently Asked Questions
What is clinical trial NCT07101094 about?
NCT07101094 is a clinical study titled "Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)". The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
What is the current status of trial NCT07101094?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-09-22. Estimated completion is 2029-05-14.
What conditions does trial NCT07101094 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07101094?
The interventions under investigation include: xanomeline and trospium chloride (X/T) therapy (DRUG).
Who is sponsoring clinical trial NCT07101094?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07101094 being conducted?
This trial has 17 study locations across California, Illinois, Maryland, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07101094's enrollment target sits among peer trials
300 57th of 315 higher than 255 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI